RS50208B - Višeslojna tableta sa kombinovanim oslobađanjem aktivne supstance - Google Patents

Višeslojna tableta sa kombinovanim oslobađanjem aktivne supstance

Info

Publication number
RS50208B
RS50208B YU36401A YU36401A RS50208B RS 50208 B RS50208 B RS 50208B YU 36401 A YU36401 A YU 36401A YU 36401 A YU36401 A YU 36401A RS 50208 B RS50208 B RS 50208B
Authority
RS
Serbia
Prior art keywords
pharmaceutically acceptable
multilayer tablet
active compound
thiazolidine
dione
Prior art date
Application number
YU36401A
Other languages
English (en)
Inventor
Robert Glinecke
Susan Marie Milosovich
William Muldoon
Vincenzo Re
Joseph Sauer
Janet Louise Skinner
Original Assignee
Smithkline Beecham Corporation,
Smithkline Beecham P.L.C.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824870.1A external-priority patent/GB9824870D0/en
Priority claimed from GBGB9912189.9A external-priority patent/GB9912189D0/en
Application filed by Smithkline Beecham Corporation,, Smithkline Beecham P.L.C., filed Critical Smithkline Beecham Corporation,
Publication of YU36401A publication Critical patent/YU36401A/sh
Publication of RS50208B publication Critical patent/RS50208B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1.Farmaceutska kompozicija pogodna za administraciju jednom na dan, naznačena time, što obuhvata : 5 a) 2mg do 12 mg 5-[4-[2-(N-metil-N-(2-piridil)amino)etoksi]benzil]tiazolidin-2,4-dion, po izboru u obliku svoje farmaceutski prihvatljive soli, estra ili solvata; i b) farmaceutski prihvatljiv nosač; gde je kompozicija višeslojna tableta pripremljena tako da obezbedi kombinaciju nemodifikovanog i kontinulanog osobađanja 5-[4-[2-(N-metil-N-(2-10 piridil)amino) etoksi] benzil]tiazolidin-2,4-diona, po izboru u obliku svoje farmaceutski prihvatljive soli, estra ili solvata, pri čemu je kontinulano oslobadanje obezbedeno matriksom kontinulanog oslobađanja odabranim od dezintegrirajućeg, nedezintegrirajućeg ili erodirajućeg matriksa. Prijava sadrži 1 nezavisan zahtev i 3 zavisna zahteva.
YU36401A 1998-11-12 1999-11-12 Višeslojna tableta sa kombinovanim oslobađanjem aktivne supstance RS50208B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9824870.1A GB9824870D0 (en) 1998-11-12 1998-11-12 Novel composition and use
GBGB9912189.9A GB9912189D0 (en) 1999-05-25 1999-05-25 Novel composition and use

Publications (2)

Publication Number Publication Date
YU36401A YU36401A (sh) 2004-05-12
RS50208B true RS50208B (sr) 2009-07-15

Family

ID=26314667

Family Applications (1)

Application Number Title Priority Date Filing Date
YU36401A RS50208B (sr) 1998-11-12 1999-11-12 Višeslojna tableta sa kombinovanim oslobađanjem aktivne supstance

Country Status (39)

Country Link
EP (3) EP1128827B1 (sr)
JP (1) JP2002529505A (sr)
KR (2) KR20060097140A (sr)
CN (1) CN1289081C (sr)
AP (2) AP1901A (sr)
AR (2) AR023700A1 (sr)
AT (1) ATE382352T1 (sr)
AU (1) AU768578B2 (sr)
BG (2) BG65444B1 (sr)
BR (1) BR9915215A (sr)
CA (1) CA2350659C (sr)
CO (1) CO5190673A1 (sr)
CY (1) CY1107909T1 (sr)
CZ (1) CZ20011628A3 (sr)
DE (1) DE69937898T2 (sr)
DK (1) DK1128827T3 (sr)
DZ (1) DZ2937A1 (sr)
EA (3) EA200702648A1 (sr)
EG (2) EG22344A (sr)
ES (1) ES2299269T3 (sr)
HK (1) HK1040909B (sr)
HR (2) HRP20010342B1 (sr)
HU (1) HUP0104307A3 (sr)
ID (1) ID29344A (sr)
IL (2) IL143003A0 (sr)
MY (1) MY135973A (sr)
NO (1) NO20012351L (sr)
NZ (2) NZ526440A (sr)
OA (1) OA11676A (sr)
PE (1) PE20001428A1 (sr)
PL (1) PL198717B1 (sr)
PT (1) PT1128827E (sr)
RS (1) RS50208B (sr)
SI (1) SI1128827T1 (sr)
SK (1) SK286937B6 (sr)
TR (2) TR200101337T2 (sr)
TW (2) TWI257305B (sr)
UY (2) UY25798A1 (sr)
WO (1) WO2000028990A1 (sr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
MY125516A (en) 1999-11-16 2006-08-30 Smithkline Beecham Plc Novel composition based on thiazolidinedione and metformin and use
EP1244468A2 (en) * 2000-01-07 2002-10-02 University Of Cincinnati Selective activation of a th1 or th2 lymphocyte regulated immune response
IL151150A0 (en) * 2001-01-31 2003-04-10 Roehm Gmbh Multiparticulate drug form comprising at least two differently coated pellet forms
JP2005514399A (ja) * 2001-12-21 2005-05-19 スミスクライン ビーチャム コーポレーション ＰＰＡＲγアクチベーターの投薬法
PE20030800A1 (es) * 2002-02-12 2003-10-31 Glaxo Group Ltd Forma de dosificacion oral de liberacion controlada
US20060286168A1 (en) * 2002-07-11 2006-12-21 Masahiko Koike Process for producing coated preparation
US7018658B2 (en) * 2002-11-14 2006-03-28 Synthon Bv Pharmaceutical pellets comprising tamsulosin
EP1589951B1 (en) * 2003-01-03 2017-08-09 Supernus Pharmaceuticals, Inc. Use of a mixture of two or more enteric materials to regulate drug release via membrane or matrix for systemic therapeutics
EP1588708A4 (en) 2003-01-29 2006-03-01 Takeda Pharmaceutical METHOD FOR PRODUCING COATED PREPARATION
ES2241478B1 (es) * 2004-02-13 2006-11-16 Lacer S.A. Preparacion farmaceutica para la liberacion sostenida de un principio farmaceuticamente activo.
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
WO2013010137A2 (en) * 2011-07-14 2013-01-17 Jacks Health Technologies Llc A composition, device and method for delayed and sustained release of brain energy molecules
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
DK173350B1 (da) 1985-02-26 2000-08-07 Sankyo Co Thiazolidinderivater, deres fremstilling og farmaceutisk paæparat indeholdende dem
JPH06779B2 (ja) 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
ATE186724T1 (de) 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008651A1 (en) 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
US5061717A (en) 1988-03-08 1991-10-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
WO1991007107A1 (en) 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
WO1992000967A1 (fr) 1990-07-03 1992-01-23 Yamanouchi Pharmaceutical Co., Ltd. Compose biheterocyclique
EP0544696B1 (en) 1990-08-23 1995-01-11 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
JPH04210683A (ja) 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
KR100249988B1 (ko) 1991-04-11 2000-04-01 로렌스 티. 마이젠헬더 티아졸리딘디온 유도체, 그의 제조방법 및 용도
US5502078A (en) * 1991-05-28 1996-03-26 Zeneca Limited Chemical compounds
TW222626B (sr) 1991-07-22 1994-04-21 Pfizer
FR2680512B1 (fr) 1991-08-20 1995-01-20 Adir Nouveaux derives de 2,4-thiazolidinedione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JPH05271204A (ja) 1992-03-26 1993-10-19 Japan Tobacco Inc 新規なトリアジン誘導体
US5264451A (en) 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
WO1993021166A1 (en) 1992-04-10 1993-10-28 Smithkline Beecham Plc Heterocyclic compounds and their use in the treatment of type ii-diabetes
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
PL174610B1 (pl) 1992-07-03 1998-08-31 Smithkline Beecham Plc Nowe związki heterocykliczne
US5326770A (en) * 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
US5232945A (en) 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
JP3256841B2 (ja) * 1996-06-27 2002-02-18 武田薬品工業株式会社 ベンズアルデヒド化合物の製造法
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
CA2284192A1 (en) * 1997-03-24 1998-10-01 Galderma Research & Development, S.N.C. Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus

Also Published As

Publication number Publication date
EP1128827B1 (en) 2008-01-02
AU768578B2 (en) 2003-12-18
OA11676A (en) 2005-01-12
TR200503846T2 (tr) 2007-01-22
ATE382352T1 (de) 2008-01-15
HK1040909B (zh) 2008-08-01
UY25800A1 (es) 2000-08-21
HUP0104307A3 (en) 2003-12-29
AP2008004490A0 (en) 2008-06-30
AU1272900A (en) 2000-06-05
HK1040909A1 (en) 2002-06-28
HRP20080117A2 (en) 2008-10-31
KR100732599B1 (ko) 2007-06-27
EA200100540A1 (ru) 2001-10-22
SI1128827T1 (sl) 2008-06-30
IL183972A0 (en) 2007-10-31
PT1128827E (pt) 2008-03-10
UY25798A1 (es) 2000-12-29
CN1289081C (zh) 2006-12-13
BG65444B1 (bg) 2008-08-29
CA2350659C (en) 2009-06-09
BG105570A (en) 2002-02-28
PL198717B1 (pl) 2008-07-31
HRP20010342B1 (en) 2008-04-30
TW200505436A (en) 2005-02-16
AP1901A (en) 2008-10-24
CA2350659A1 (en) 2000-05-25
EP1917962A1 (en) 2008-05-07
CZ20011628A3 (cs) 2001-12-12
WO2000028990A1 (en) 2000-05-25
DE69937898T2 (de) 2009-01-02
MY135973A (en) 2008-07-31
SK6432001A3 (en) 2001-12-03
EA200702648A1 (ru) 2008-10-30
CN1333683A (zh) 2002-01-30
AR023700A1 (es) 2002-09-04
EP1815855A1 (en) 2007-08-08
IL143003A0 (en) 2002-04-21
NZ526440A (en) 2005-01-28
ES2299269T3 (es) 2008-05-16
DK1128827T3 (da) 2008-04-28
KR20010073229A (ko) 2001-07-31
DZ2937A1 (fr) 2004-03-15
EP1128827A1 (en) 2001-09-05
EA200601144A1 (ru) 2007-02-27
YU36401A (sh) 2004-05-12
CO5190673A1 (es) 2002-08-29
JP2002529505A (ja) 2002-09-10
NO20012351D0 (no) 2001-05-11
KR20060097140A (ko) 2006-09-13
DE69937898D1 (de) 2008-02-14
PE20001428A1 (es) 2001-02-08
NO20012351L (no) 2001-07-04
NZ511611A (en) 2003-10-31
EG24463A (en) 2009-07-16
HRP20010342A2 (en) 2002-06-30
TWI257305B (en) 2006-07-01
CY1107909T1 (el) 2013-09-04
SK286937B6 (sk) 2009-07-06
BR9915215A (pt) 2001-07-31
TWI246920B (en) 2006-01-11
AR023699A1 (es) 2002-09-04
HUP0104307A2 (hu) 2002-07-29
PL348153A1 (en) 2002-05-06
EG22344A (en) 2002-12-31
EA007608B1 (ru) 2006-12-29
ID29344A (id) 2001-08-23
BG109893A (bg) 2008-11-28
TR200101337T2 (tr) 2001-11-21

Similar Documents

Publication Publication Date Title
HRP20010343B1 (en) Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
RS50208B (sr) Višeslojna tableta sa kombinovanim oslobađanjem aktivne supstance
RS50303B (sr) Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem
DE60032749D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
RS51343B (sr) Nova kompozicija i njena upotreba
NO944803D0 (no) Farmasöytisk preparat for kontrollert frigivelse
YU71894A (sh) Novi farmaceutski preparat sa difuziono-osmotskom kontrolom oslobađanja leka i postupak za dobivanje istog
ES2331046T1 (es) Formulacion de liberacion controlada.
TR200003788A2 (tr) Yavaş salımlı oral dozaj bileşim.
DE69922676D1 (de) N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden
BR9914251A (pt) Formulações orais de liberação sustentada
MA29281B1 (fr) Forme posologique orale au rosiglitazone
IL146312A (en) 3-(2-oxo-pyridinyl)-acylamino-propanoic acid derivatives that inhibit the binding of integrins to their receptors and pharmaceutical compositions comprising the same
AP2003002763A0 (en) Controlled release formulations for oral administration
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
CO5271676A1 (es) Metodo para administrar un inhibidor de fosfodiesterasa 4
AR015894A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4-diona e insulina para la preparacion de un medicamento y composicion farmaceuticaque contiene dichos compuestos
TR200002790T2 (tr) 5-(4-(2-(N-metil-N-2-piridil) amino)etoksi) benzil)tiazolidin-2,4-dion içeren terkip
Kihara et al. AT-1015, a novel serotonin (5-HT) 2 receptor antagonist, blocks vascular and platelet 5-HT2A receptors and prevents the laurate-induced peripheral vascular lesion in rats
RS50130B (sr) Farmaceutska kompozicija 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil) tiazolidin-2,4-diona
BR0312410A (pt) Formulações farmacêuticas de liberação controlada
RS50291B (sr) Novi galenski oblik molsidomina za oralnu upotrebu sa produženim delovanjem
AP1738A (en) Sodium salts of 5-[4-[2-(N-Methyl -N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione.
BR0112982A (pt) Sal tartarato de derivado de tiazolidinadiona
BR0111508A (pt) Iodidrato de 5-(4-(2-(n-metil-(2-piridil) amino) etóxi) benzil) tiazolidina-2,4diona como substância farmacEutica